Nurix Therapeutics Presents New Preclinical and Phase 1 Translational Data Supporting Bexobrutideg (NX-5948) in Chronic Spontaneous Urticaria at the 2026 Society for Investigative Dermatology Annual M
Go back to Nurix Therapeutics Presents New Preclinical and Phase 1 Translational Data Supporting Bexobrutideg (NX-5948) in Chronic Spontaneous Urticaria at the 2026 Society for Investigative Dermatology Annual M| (NASDAQ: NRIX) | Delayed: 17.55 +0.43 (2.51%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $17.12 | 52 Week High | $ | |||
| Open | $17.64 | 52 Week Low | $ | |||
| Day High | $17.89 | P/E | N/A | |||
| Day Low | $16.95 | EPS | $ | |||
| Volume | 4,250,981 | |||||
